An additional real-world study is the already quoted study by Guimbellot et al. [98] that assessed the effects of IVA after 5.5 years of treatment in CF patients ≥ 6 years old, with at least one copy of G551D CFTR mutations (n = 96). The gene discussed is CFTR; the disease is cystic fibrosis.